HRTX Summer Marketing DD
TLDR; $HRTX marketing this summer could be huge . PT low of 22 and high of ~70 by Q3 . Rated buy. Currently sits at 13.40
Heron Therapeutics recently had their newest medication , ZYNRELEF, approved by the FDA and are planning on pushing out the product THIS summer. Helps that they just got $150m to do it with too
Drug info provided by website: “ZYNRELEF is the first and only extended-release dual-acting local anesthetic (DALA). Its formulation combines bupivacaine, an amide-type local anesthetic, with a low dose of meloxicam, a nonsteroidal anti-inflammatory drug (NSAID). They work synergistically in a novel Biochronomer® extended-release polymer that provides controlled diffusion of both ingredients simultaneously over 72 hours at the surgical site.1-5 ZYNRELEF is the only local anesthetic considered by FDA to be extended-release, based on superiority to bupivacaine through 72 hours.”
TLDR ^ non-opioid painkiller for post-surgery pain
They’ve also revamped their website and added more info on ZYNRELEF. I see this as incredibly bullish and look forward to Q3 earnings.
Edit: Adding on, they’ve priced their product at a lower price than competitors. This will surely give them more exposure due to being the less expensive medication. Ethically speaking, they also will aid in stumping the opioid addiction that many painkillers cause.
HRTX Provided Slides from conference today (6/1)
I’d see slide 8 for comparisons to others
I’d give their website a look. What’s more, is that with the pandemic being handled, there will be more freedom and thus, more fuckers getting injured and needing surgery.
You do your own research, as I take no responsibility for any of your decisions. Good luck
Pos: 250 shares
Submitted June 02, 2021 at 04:22AM by FellaFromCali https://ift.tt/3ieEBmq
